MX2022007626A - Combinaciones. - Google Patents

Combinaciones.

Info

Publication number
MX2022007626A
MX2022007626A MX2022007626A MX2022007626A MX2022007626A MX 2022007626 A MX2022007626 A MX 2022007626A MX 2022007626 A MX2022007626 A MX 2022007626A MX 2022007626 A MX2022007626 A MX 2022007626A MX 2022007626 A MX2022007626 A MX 2022007626A
Authority
MX
Mexico
Prior art keywords
combinations
disease
treating
compounds
condition
Prior art date
Application number
MX2022007626A
Other languages
English (en)
Inventor
Brant Clayton Boren
Kevin Duane Bunker
Fernando Donate
Peter Qinhua Huang
Jiali Li
Hooman Izadi
Ahmed Abdi Samatar
Joseph Robert Pinchman
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of MX2022007626A publication Critical patent/MX2022007626A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

En la presente descripción se describen combinaciones de compuestos para tratar una enfermedad o afección, tal como el cáncer. Una combinación de compuestos para tratar una enfermedad o afección puede incluir un inhibidor de WEE1 y un inhibidor de Bcl-2, junto con sales farmacéuticamente aceptables de cualquiera de los anteriores.
MX2022007626A 2019-12-20 2020-12-16 Combinaciones. MX2022007626A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962952039P 2019-12-20 2019-12-20
PCT/US2020/065409 WO2021127044A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (1)

Publication Number Publication Date
MX2022007626A true MX2022007626A (es) 2022-09-23

Family

ID=76478095

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007626A MX2022007626A (es) 2019-12-20 2020-12-16 Combinaciones.

Country Status (12)

Country Link
US (1) US20230008362A1 (es)
EP (1) EP4069235A4 (es)
JP (1) JP2023508328A (es)
KR (1) KR20220119442A (es)
CN (1) CN115427042A (es)
AU (1) AU2020407070A1 (es)
BR (1) BR112022012281A2 (es)
CA (1) CA3165472A1 (es)
IL (1) IL294080A (es)
MX (1) MX2022007626A (es)
TW (1) TW202132299A (es)
WO (1) WO2021127044A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276802B2 (en) 2018-03-09 2023-09-01 Recurium Ip Holdings Llc Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones
EP4431511A1 (en) * 2021-11-09 2024-09-18 Hangzhou Glubio Pharmaceutical Co. Ltd. Wee1 protein kinase degradation agent and use thereof
EP4447965A1 (en) * 2021-12-15 2024-10-23 Recurium IP Holdings, LLC Triple therapy combinations of bcl-2 inhibitors, wee-1 inhibitors and other chemotherapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111094253B (zh) * 2017-08-01 2023-08-29 里科瑞尔姆Ip控股有限责任公司 1,2-二氢-3H-吡唑并[3,4-d]嘧啶-3-酮类似物
WO2019037678A1 (zh) * 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用
WO2019074979A1 (en) * 2017-10-09 2019-04-18 Girafpharma, Llc HETEROCYCLIC COMPOUNDS AND USES THEREOF
AU2019207608B2 (en) * 2018-01-10 2024-03-28 Recurium Ip Holdings, Llc Benzamide compounds
IL276802B2 (en) * 2018-03-09 2023-09-01 Recurium Ip Holdings Llc Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones

Also Published As

Publication number Publication date
EP4069235A1 (en) 2022-10-12
AU2020407070A1 (en) 2022-07-14
IL294080A (en) 2022-08-01
US20230008362A1 (en) 2023-01-12
CN115427042A (zh) 2022-12-02
BR112022012281A2 (pt) 2022-08-30
WO2021127044A1 (en) 2021-06-24
JP2023508328A (ja) 2023-03-02
CA3165472A1 (en) 2021-06-24
EP4069235A4 (en) 2024-01-10
TW202132299A (zh) 2021-09-01
KR20220119442A (ko) 2022-08-29

Similar Documents

Publication Publication Date Title
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
MX2022007626A (es) Combinaciones.
MX2019008158A (es) Terapia de combinacion para el tratamiento del cancer.
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
MX2022007628A (es) Combinaciones.
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
MX2023008954A (es) Inhibidores de los receptores erbb.
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
MX2020012497A (es) Moduladores de la expresion de apol1.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
EP4365300A3 (en) Treatment/prevention of disease by linc complex inhibition
PH12017501882A1 (en) Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
MX2021005038A (es) Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas.
MX2022007623A (es) Combinaciones.
CO2017009182A2 (es) Cepas bacterianas productoras de histamina para tratamiento del cáncer
ZA202206308B (en) Ezetimibe and curcumin for use in cancer treatment
MX2022007625A (es) Combinaciones.
MX2021014458A (es) Compuestos triciclicos.
MX2021009717A (es) Sulfonamidas biciclicas.
EP3970793A4 (en) AGENT FOR THE PREVENTION, APPEAL OR TREATMENT OF PERIODONTAL DISEASE
WO2020185651A3 (en) Compositions and methods for treating huntington's disease